REDEFINING EXPECTATIONS
Pursuing the full potential of engineered RNA therapeutics for neurological diseases
Tovero Bio is harnessing the promise of vectorized RNAi technology to redefine expectations for the use of advanced precision medicine in genetic disease. Our therapeutic candidates leverage existing cellular machinery, mirroring innate processes to directly address genetic drivers of disease. Our goal is to transform outcomes for people with challenging neurological diseases who have no therapeutic options today.
NEUROLOGY FOCUS
Addressing Unmet Needs in Neurological Disease, Starting with Charcot-Marie-Tooth Disease Type 1A (CMT1A)
CMT Type 1A is one of the most common rare diseases
Progressively disability leads to loss of independence and risk of fatal complications
No therapies are approved today that address the genetic driver of disease
Symptomatic care today is inadequate to support long-term outcome goals
FOCUSED PIPELINE
Targeted pipeline leverages vectorized RNAi to address Charcot-Marie-Tooth disease, with opportunities to expand into additional autosomal dominant neurological diseases.
OUR TECHNOLOGY
Our proprietary, pioneering RNAi technology platform is an engine for novel RNAi therapeutics
Building upon decades of pioneering efforts in RNA research, we have developed proprietary constructs that effectively address the limitations of early genetic therapies. Our innovative approach involves the precise targeting of dominant disease-driving genes, a strategy that holds the key to managing disease manifestations, enhancing the clinical profile and delivering an improved patient experience.
OUR TEAM
A veteran team combining drug discovery, delivery and venture expertise and a shared, tenacious innovation mindset.
